Stanford Found an Aging Switch in Mice, and the Aspirin Takeaway Everyone Will Draw Is Wrong
A new Stanford study is about to get badly misread, and I would rather explain the real finding before that happens than clean it up afterward. The team, publishing in Science, found a specific reason chronic inflammation tracks with aging, and they named the exact receptor responsible. Because of how that receptor gets triggered, the obvious consumer takeaway people will reach for is wrong, and the researchers say so themselves.
- Stanford researchers, publishing in Science, found that aging tissue resident macrophages, the body's garbage collection crew, lose the ability to clear out worn out neutrophils, and that failure drives inflammation and decline across the whole body.
- Deleting one receptor, EP2, on those macrophages in mice kept them lean, strong, sharp and biologically younger into old age. Of 71 blood proteins that normally change with age, 59 held at youthful levels.
- Because aspirin lowers the hormone, PGE2, that activates EP2, this will get reported as an NSAID longevity hack. The researchers want the opposite: a selective EP2 blocker, precisely because broadly suppressing PGE2 interferes with other necessary signaling.
- Every functional result here is in mice, and no approved drug currently blocks EP2 selectively. This is a mechanism worth watching, not a protocol to follow.
What Stanford actually found
Your body makes roughly 100 billion neutrophils a day, first responder white blood cells that are short lived and start showing signs of senescence within 8 to 12 hours of entering the bloodstream. Once senescent, they leak damaging chemicals and drive inflammation. Clearing them out is the job of tissue resident macrophages, long lived immune cells that settle into your organs before birth and stay there for life, described by the study's senior author as the body's garbage collection crew. With age, two things rise together: PGE2, an inflammatory signaling hormone, and EP2, the receptor for it that sits in large numbers on those macrophages. More PGE2 hitting more EP2 progressively weakens the macrophages' ability to engulf neutrophils, so senescent neutrophils pile up in blood and tissue, and the inflammation feeds itself.
A stained blood smear showing a neutrophil, the multilobed purple cell at center, the type of white blood cell this study is about
MarkgirtonCC BY 4.0
Illustrative: a real human neutrophil, not from this study and not showing senescence or macrophage clearance.
When researchers deleted EP2 in mice at 4 to 6 months old, their teenage years, and compared them at 23 to 25 months, roughly a human's sixties or seventies, the difference was striking. Of 71 blood proteins that normally change significantly with age, 59 stayed at youthful levels, many of them originating in the liver. The mice were leaner, with less visceral fat and more muscle, matched young mice on organ function tests, speed, balance and grip strength, and held closer to young mouse performance on memory and maze navigation. A separate test gave normal 22 month old mice an experimental EP2 blocking drug for two months, and total and senescent neutrophil counts moved back toward youthful levels.
The mistake everyone is about to make
Aspirin and other NSAIDs lower PGE2, so the shorthand version of this story practically writes itself: take aspirin for longevity. That is exactly backward, and the researchers are explicit about why. NSAIDs suppress PGE2 broadly across the whole body, which interferes with other prostaglandins that do necessary, beneficial work, and PGE2 itself is beneficial through receptors other than EP2. The reason this team wants a selective EP2 blocker, a drug that does not currently exist, is precisely because the blunt approach NSAIDs already take is the wrong tool for this job. In a large human liver cell database, older livers showed the same pattern found in the mice, more neutrophil accumulation, more neutrophil senescence, declining macrophage function and elevated EP2, more pronounced in diseased livers, which the senior author says is the first time these changes have been observed directly in human cells.
the blunt approach NSAIDs already take is the wrong tool for this job
Honest caveat
Every functional result in this study, leanness, grip strength, memory, organ function, came from mice. The human component is observational pattern matching in a liver cell database, not a human intervention. There is no approved drug that can selectively shut down EP2 activity, and the compound used in the older mice was experimental. NSAIDs are explicitly not the takeaway here, and any content implying aspirin or ibuprofen can approximate this effect would be unsupported by the paper and potentially harmful. The headline organ protection result came from mice whose EP2 was deleted from adolescence, which models lifelong absence, not a treatment started in mid life. That is a meaningfully bigger effect than the two month drug experiment in 22 month old mice, which normalized neutrophil counts but did not repeat the full genetic phenotype. This is a single lab, unreplicated, though it builds on the same group's prior published work, and mouse to human longevity translation generally has a poor track record.
What this means for you
There is nothing to buy or take here, and that is actually the honest, useful part of this story. This is a mechanism worth understanding and watching, not a protocol. If you see EP2 blockers, PGE2 inhibitors or anything claiming to replicate this research marketed as a supplement or a longevity hack in the near future, that claim is ahead of the science. The real value of this study, for anyone who reads Sama Says regularly, is a clear, correct explanation of a mechanism you are going to keep hearing about, delivered before the supplement industry has a chance to get ahead of the actual researchers on what it means.
Primary sources
Common questions
Should I take aspirin or ibuprofen for longevity based on this study?
No, and the researchers are explicit about this. NSAIDs suppress PGE2 broadly, which interferes with other prostaglandins that do necessary work in the body, and PGE2 itself is beneficial through receptors other than EP2. The researchers want a selective EP2 blocker precisely because the blunt, broad approach NSAIDs take is the wrong tool. No approved drug that selectively blocks EP2 currently exists.
Is this a treatment I can use right now?
No. Every functional result, leanness, grip strength, memory, organ function, came from mice, and the strongest results came from mice whose EP2 was deleted genetically from adolescence, which models lifelong absence rather than a treatment given later in life. A separate two month drug experiment in older mice showed a narrower result, normalized neutrophil counts, using an experimental compound that is not an approved drug.
Does this apply to humans?
The mechanism shows up in human liver cell data, with older and diseased human livers displaying the same pattern of neutrophil buildup and declining macrophage function seen in the mice. That is an observational, associative finding in cells, not a human intervention. Every functional outcome remains mouse only, and mouse to human longevity translation has a poor track record generally.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.